Terms: = Lymphoma AND NCOR2, SMRTE-tau, 9612, ENSG00000196498, SMRTE, TNRC14, TRAC-1, SMRT, CTG26, TRAC1
36 results:
1. Selectively targeting BCL6 using a small molecule inhibitor is a potential therapeutic strategy for ovarian cancer.
Wu M; Xie J; Xing Y; Zhang L; Chen H; Tang B; Zhou M; Lv S; Huang D; Jian S; Zhou C; Liu M; Guo W; Chen Y; Yi Z
Int J Biol Sci; 2024; 20(2):486-501. PubMed ID: 38169532
[TBL] [Abstract] [Full Text] [Related]
2. Diffuse large B-cell lymphoma and red cell autoimmunity: clinical role and pathogenesis.
Coombes C; Horikawa K; Jain S; Jiang S; Lim JH; Saxena K; Shadbolt B; Smyth L; Tobin J; Talaulikar D
Pathology; 2023 Feb; 55(1):104-112. PubMed ID: 36420560
[TBL] [Abstract] [Full Text] [Related]
3. Targeted sequencing reveals the relationship between mutations and patients' clinical indicators, blood cell counts and early progression in diffuse large-B cell lymphoma.
Ma G; Gao Y; Jing X; He C; Liu H; Wu X; Gao Z; Li Y; Zhang S; Zhao G
Leuk Lymphoma; 2023 Jan; 64(1):140-150. PubMed ID: 36215154
[TBL] [Abstract] [Full Text] [Related]
4. TBL1X: At the crossroads of transcriptional and posttranscriptional regulation.
Pray BA; Youssef Y; Alinari L
Exp Hematol; 2022 Dec; 116():18-25. PubMed ID: 36206873
[TBL] [Abstract] [Full Text] [Related]
5. Identification of the novel HLA-E*01:03:02:25 allele in an acute lymphoblastic leukemia patient.
Williams HB; Lucas JAM; Georgiou X; Marsh SGE; Mayor NP
HLA; 2022 Jul; 100(1):90-92. PubMed ID: 35092184
[TBL] [Abstract] [Full Text] [Related]
6. The uncharacterized SANT and BTB domain-containing protein SANBR inhibits class switch recombination.
Zheng S; Matthews AJ; Rahman N; Herrick-Reynolds K; Sible E; Choi JE; Wishnie A; Ng YK; Rhodes D; Elledge SJ; Vuong BQ
J Biol Chem; 2021; 296():100625. PubMed ID: 33831416
[TBL] [Abstract] [Full Text] [Related]
7. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia.
Waanders E; Gu Z; Dobson SM; Antić Ž; Crawford JC; Ma X; Edmonson MN; Payne-Turner D; van de Vorst M; Jongmans MCJ; McGuire I; Zhou X; Wang J; Shi L; Pounds S; Pei D; Cheng C; Song G; Fan Y; Shao Y; Rusch M; McCastlain K; Yu J; van Boxtel R; Blokzijl F; Iacobucci I; Roberts KG; Wen J; Wu G; Ma J; Easton J; Neale G; Olsen SR; Nichols KE; Pui CH; Zhang J; Evans WE; Relling MV; Yang JJ; Thomas PG; Dick JE; Kuiper RP; Mullighan CG
Blood Cancer Discov; 2020 Jul; 1(1):96-111. PubMed ID: 32793890
[TBL] [Abstract] [Full Text] [Related]
8. TBL1XR1 Mutations Drive Extranodal lymphoma by Inducing a Pro-tumorigenic Memory Fate.
Venturutti L; Teater M; Zhai A; Chadburn A; Babiker L; Kim D; Béguelin W; Lee TC; Kim Y; Chin CR; Yewdell WT; Raught B; Phillip JM; Jiang Y; Staudt LM; Green MR; Chaudhuri J; Elemento O; Farinha P; Weng AP; Nissen MD; Steidl C; Morin RD; Scott DW; Privé GG; Melnick AM
Cell; 2020 Jul; 182(2):297-316.e27. PubMed ID: 32619424
[TBL] [Abstract] [Full Text] [Related]
9. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
[TBL] [Abstract] [Full Text] [Related]
10. HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy.
Deng S; Hu Q; Zhang H; Yang F; Peng C; Huang C
Mol Cancer Ther; 2019 May; 18(5):900-908. PubMed ID: 30824609
[TBL] [Abstract] [Full Text] [Related]
11. Two novel alleles, HLA-A*32:01:01:09 and 32:01:01:10, identified by Pacific Bioscience's smrt sequencing.
Cambridge CA; Turner TR; Georgiou X; Marsh SGE; Mayor NP
HLA; 2018 Dec; 92(6):409-411. PubMed ID: 30311452
[TBL] [Abstract] [Full Text] [Related]
12. Identification of Thiourea-Based Inhibitors of the B-Cell lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H; Linhares BM; Yu W; Cardenas MG; Ai Y; Jiang W; Winkler A; Cohen S; Melnick A; MacKerell A; Cierpicki T; Xue F
J Med Chem; 2018 Sep; 61(17):7573-7588. PubMed ID: 29969259
[TBL] [Abstract] [Full Text] [Related]
13. Panel Sequencing Shows Recurrent Genetic FAS Alterations in Primary Cutaneous Marginal Zone lymphoma.
Maurus K; Appenzeller S; Roth S; Kuper J; Rost S; Meierjohann S; Arampatzi P; Goebeler M; Rosenwald A; Geissinger E; Wobser M
J Invest Dermatol; 2018 Jul; 138(7):1573-1581. PubMed ID: 29481902
[TBL] [Abstract] [Full Text] [Related]
14. Targeting HDAC3 in CREBBP-Mutant lymphomas Counterstrikes Unopposed Enhancer Deacetylation of B-cell Signaling and Immune Response Genes.
Höpken UE
Cancer Discov; 2017 Jan; 7(1):14-16. PubMed ID: 28062671
[TBL] [Abstract] [Full Text] [Related]
15. CREBBP Inactivation Promotes the Development of HDAC3-Dependent lymphomas.
Jiang Y; Ortega-Molina A; Geng H; Ying HY; Hatzi K; Parsa S; McNally D; Wang L; Doane AS; Agirre X; Teater M; Meydan C; Li Z; Poloway D; Wang S; Ennishi D; Scott DW; Stengel KR; Kranz JE; Holson E; Sharma S; Young JW; Chu CS; Roeder RG; Shaknovich R; Hiebert SW; Gascoyne RD; Tam W; Elemento O; Wendel HG; Melnick AM
Cancer Discov; 2017 Jan; 7(1):38-53. PubMed ID: 27733359
[TBL] [Abstract] [Full Text] [Related]
16. smrt Sequencing for Parallel Analysis of Multiple Targets and Accurate SNP Phasing.
Guo X; Lehner K; O'Connell K; Zhang J; Dave SS; Jinks-Robertson S
G3 (Bethesda); 2015 Oct; 5(12):2801-8. PubMed ID: 26497143
[TBL] [Abstract] [Full Text] [Related]
17. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.
Crescenzo R; Abate F; Lasorsa E; Tabbo' F; Gaudiano M; Chiesa N; Di Giacomo F; Spaccarotella E; Barbarossa L; Ercole E; Todaro M; Boi M; Acquaviva A; Ficarra E; Novero D; Rinaldi A; Tousseyn T; Rosenwald A; Kenner L; Cerroni L; Tzankov A; Ponzoni M; Paulli M; Weisenburger D; Chan WC; Iqbal J; Piris MA; Zamo' A; Ciardullo C; Rossi D; Gaidano G; Pileri S; Tiacci E; Falini B; Shultz LD; Mevellec L; Vialard JE; Piva R; Bertoni F; Rabadan R; Inghirami G;
Cancer Cell; 2015 Apr; 27(4):516-32. PubMed ID: 25873174
[TBL] [Abstract] [Full Text] [Related]
18. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma.
Barneda-Zahonero B; Collazo O; Azagra A; Fernández-Duran I; Serra-Musach J; Islam AB; Vega-García N; Malatesta R; Camós M; Gómez A; Román-González L; Vidal A; López-Bigas N; Villanueva A; Esteller M; Parra M
Cell Death Dis; 2015 Feb; 6(2):e1635. PubMed ID: 25675295
[TBL] [Abstract] [Full Text] [Related]
19. Molecular dynamics analysis of the interaction between the human BCL6 BTB domain and its smrt, NcoR and BCOR corepressors: the quest for a consensus dynamic pharmacophore.
Granadino-Roldán JM; Obiol-Pardo C; Pinto M; Garzón A; Rubio-Martínez J
J Mol Graph Model; 2014 May; 50():142-51. PubMed ID: 24793055
[TBL] [Abstract] [Full Text] [Related]
20. The ansamycin antibiotic, rifamycin SV, inhibits BCL6 transcriptional repression and forms a complex with the BCL6-BTB/POZ domain.
Evans SE; Goult BT; Fairall L; Jamieson AG; Ko Ferrigno P; Ford R; Schwabe JW; Wagner SD
PLoS One; 2014; 9(3):e90889. PubMed ID: 24595451
[TBL] [Abstract] [Full Text] [Related]
[Next]
